4/A: Aquestive Therapeutics Executive Alexander Schobel Reports Tax Withholding Share Transaction
SEC Form 4/A
Alexander Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, reports the withholding of shares to cover tax obligations related to vested Restricted Stock Units.
Summary
- On March 9, 2024, Alexander Mark Schobel, Chief Innovation/Tech Officer of Aquestive Therapeutics, Inc., had 9,645 shares of common stock withheld by the issuer to satisfy tax obligations.
- The shares were withheld at a price of $4.88 per share.
- Following the transaction, Schobel directly owns 980,726 shares of Aquestive Therapeutics common stock.
- This Form 4/A is an amendment to a previous filing on March 12, 2024, to correct the number of shares withheld for tax obligations.
Sentiment
Score: 5
Explanation: This is a neutral transaction related to tax obligations. It doesn't indicate positive or negative sentiment towards the company.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It doesn't necessarily reflect a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/09/2024 | Date of the share withholding transaction. |
| 03/12/2024 | Date of the original Form 4 filing that this amendment corrects. |
| 10/02/2024 | Date of signature on the amended form. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.